SynthesisMayo Clinic proceedings2011
Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.
Synthesis in Mayo Clinic proceedings, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Cardiovascular diabetology · 2016Pooled it
- Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review.Cardiovascular diabetology · 2013Pooled it
- Acute effects of an oral supplement of (-)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects.Food & function · 2014Trial
- Effects of Glycemic Control on Hearing Outcomes in Diabetes Patients With Idiopathic Sudden Sensorineural Hearing Loss.The journal of international advanced otology · 2021Article
- Upregulation of GABA receptor promotes long-term potentiation and depotentiation in the hippocampal CA1 region of mice with type 2 diabetes mellitus.Experimental and therapeutic medicine · 2019Article
- Investigation on the Enzymatic Profile of Mulberry Alkaloids by Enzymatic Study and Molecular Docking.Molecules (Basel, Switzerland) · 2019Article
- The effect of continuity of care on the incidence of end-stage renal disease in patients with newly detected type 2 diabetic nephropathy: a retrospective cohort study.BMC nephrology · 2018Article
- Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.Journal of the Endocrine Society · 2017Review
- The accuracy of self-reported drug ingestion histories in emergency department patients.Journal of clinical pharmacology · 2015Article
- Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?World journal of diabetes · 2014 · on this mapReview
- Managing sedentary behavior to reduce the risk of diabetes and cardiovascular disease.Current diabetes reports · 2014Review
- The case for: hypoglycemia is of cardiovascular importance.Diabetes care · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (DM) is a major cardiovascular (CV) risk factor and, as such, is considered a coronary artery disease risk equivalent. Although glycemic control is associated with decreased CV events epidemiologically, many prospective clinical trials have failed to conclusively demonstrate that aggressive glycemic control improves the CV prognosis of patients with type 2 DM, especially those with long-standing DM. Many therapies for type 2 DM with widely divergent mechanisms of action are available. Some of these drugs, in addition to their glucose-lowering actions, have properties that may reduce or increase CV events. Agents that lower both insulin resistance and postprandial hyperglycemia while at the same time avoiding hypoglycemia may be beneficial for CV health. This article reviews the evidence regarding the use of these agents and appropriate glycemic control targets for improving the adverse CV prognosis associated with type 2 DM. We conducted a systematic review of English articles using MEDLINE and the Cochrane Controlled Trials Register (1970-2010) using the following search terms: cardiovascular disease, randomized trials, hypoglycemia, and insulin resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.